Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
02
07
2019
accepted:
20
08
2019
entrez:
9
11
2019
pubmed:
9
11
2019
medline:
9
11
2019
Statut:
epublish
Résumé
Cardiovascular disease (CVD) is the leading cause of death in patients with nonalcoholic fatty liver disease (NAFLD). The current analysis expands the knowledge on atherogenic lipid profiles in NAFLD by modeling changes in low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in a prospectively enrolling real-life study cohort to inform physicians on the cardiovascular (CV) event risk based on these changes. A total of 304 patients with histologically confirmed NAFLD were included (mean age, 52 years; equal sex distribution). Of these, 129 (42.4%) patients exhibited a NAFLD activity score ≥4 and 186 (61.2%) had at least intermediate fibrosis ≥F2. The median TC levels were 209 mg/dL (interquartile range [IQR], 183, 239), LDL-C 131 mg/dL (IQR, 103, 152), and high-density lipoprotein cholesterol (HDL-C) 45 mg/dL (IQR, 38, 52). Only 16.9% of patients received lipid-lowering therapy. According to the LDL/HDL ratio, 69 (23.7%) patients exhibited a high CV risk. The 10-year CV event risk according to the Framingham risk score (FRS) was low in 91 (41.2%), intermediate in 59 (26.7%), and high in 71 (32.1%) patients and higher in the ≥F2 NAFLD population. A moderate increase in LDL-C levels by 20 mg/dL led to a transition of 20% of patients into the high-risk group when assessing the LDL/HDL ratio. According to the FRS, 6 (2.7%) patients moved from low to intermediate and 11 (4.9%) from intermediate to high CV risk.
Identifiants
pubmed: 31701071
doi: 10.1002/hep4.1428
pii: HEP41428
pmc: PMC6824213
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1472-1481Informations de copyright
© 2019 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.
Références
Nutr Metab Cardiovasc Dis. 2016 Nov;26(11):1039-1047
pubmed: 27484755
Hepatology. 2015 May;61(5):1547-54
pubmed: 25125077
Circulation. 1998 May 12;97(18):1837-47
pubmed: 9603539
Diabetes Obes Metab. 2016 Sep;18(9):936-40
pubmed: 27109453
Circulation. 2008 Feb 12;117(6):743-53
pubmed: 18212285
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
J Hepatol. 2016 Sep;65(3):589-600
pubmed: 27212244
Hepatology. 2017 May;65(5):1557-1565
pubmed: 28130788
Vasc Health Risk Manag. 2009;5:757-65
pubmed: 19774217
Endocr Pract. 2017 Apr;23(Suppl 2):1-87
pubmed: 28437620
JAMA. 2007 Feb 7;297(5):499-508
pubmed: 17284700
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Clin Gastroenterol Hepatol. 2012 Jun;10(6):646-50
pubmed: 22245962
N Engl J Med. 2019 Jan 3;380(1):23-32
pubmed: 30415637
J Am Heart Assoc. 2019 Jun 4;8(11):e011433
pubmed: 31137992
Hepatology. 2018 May;67(5):1726-1736
pubmed: 28941364
J Hepatol. 2018 Feb;68(2):353-361
pubmed: 29223369
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
Aliment Pharmacol Ther. 2019 Oct;50(8):930-939
pubmed: 31342533
Gastroenterology. 2015 Mar;148(3):547-55
pubmed: 25461851
Gut. 2017 Jun;66(6):1138-1153
pubmed: 28314735
J Hepatol. 2012 Feb;56(2):374-80
pubmed: 21889469
Aliment Pharmacol Ther. 2018 Nov;48(10):1109-1116
pubmed: 30288767
Hepatology. 2015 Sep;62(3):773-83
pubmed: 25914296
Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44
pubmed: 23507799
J Hepatol. 2018 Oct;69(4):896-904
pubmed: 29886156
J Hepatol. 2013 Jan;58(1):155-68
pubmed: 22885388
Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):425-439
pubmed: 29713021
J Am Coll Cardiol. 2016 Apr 26;67(16):1965-6
pubmed: 27102512
J Hepatol. 2018 Mar;68(3):476-484
pubmed: 29107150
JAMA. 2016 Nov 15;316(19):2008-2024
pubmed: 27838722
Clin Diabetes. 2019 Jan;37(1):65-72
pubmed: 30705499
Curr Opin Lipidol. 2011 Dec;22(6):479-88
pubmed: 22002020
Circulation. 2008 Jun 10;117(23):3002-9
pubmed: 18519851
Lancet. 2015 Mar 14;385(9972):956-65
pubmed: 25468160